A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents
Sponsor: Hoffmann-La Roche
Listed as NCT00940628, this PHASE3 trial focuses on Obesity and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Kazan', Russia , Khabarovsk, Russia , Krasnodar, Russia , Krasnoyarsk, Russia , Moscow, Russia , Nizhny Novgorod, Russia , Novosibirsk, Russia , Samara, Russia , Tyumen, Russia , Yaroslavl, Russia and 1 more location